A randomized controlled phase II clinical trial comparing ONO‐4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis

BACKGROUND: Prostaglandin D(2) (PGD (2)) is primarily produced by mast cells and is contributing to the nasal symptoms including nasal obstruction and rhinorrhea. OBJECTIVE: This study aimed to evaluate the efficacy and safety of a novel PGD (2) receptor 1 (DP1) antagonist, ONO‐4053, in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, K., Hashiguchi, K., Takeda, T., Baba, K., Kitagoh, H., Miho, H., Tomomatsu, H., Yamaguchi, S., Odani, M., Yamamotoya, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638107/
https://www.ncbi.nlm.nih.gov/pubmed/28378369
http://dx.doi.org/10.1111/all.13174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638107/
https://www.ncbi.nlm.nih.gov/pubmed/28378369
http://dx.doi.org/10.1111/all.13174

Ejemplares similares